Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

The tumor microenvironment (TME) in ovarian cancer (OC) is characterized by immune suppression, due to an abundance of suppressive immune cells populations. To effectively enhance the activity of immune checkpoint inhibition (ICI), there is a need to identify agents that target these immunosuppressi...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul G. Pavicic, Patricia A. Rayman, Shadi Swaidani, Amit Rupani, Vladimir Makarov, Charles S. Tannenbaum, Robert P. Edwards, Anda M. Vlad, C. Marcela Diaz-Montero, Haider Mahdi
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Ovarian cancer
immunotherapy
Interleukin 12
checkpoint blockade
myeloid cells
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2198185
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items